Cited by 85Barrier Structure and Function StudiesNanoparticle-Based Drug DeliveryRNA Interference and Gene Delivery

Application progress of RVG peptides to facilitate the delivery of therapeutic agents into the central nervous system

Open access
Wang, Qinghua, Cheng, Shang, Qin, Fen, Fu, Ailing, Fu, Chen·2021·RSC Advances

Abstract

Rabies virus glycoprotein (RVG) peptides have been developed to deliver drugs for CNS diseases. In the present review, RVG-mediated drug delivery systems are summarised, which can deliver almost all small molecules and macromolecule agents.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1039/d1ra00550b

Cites

108 of 108 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • RVG29 modification can significantly improve the targeting capability of EVs toward neurons both in vivo and in vitro compared to native EVs.

    “RVG 29 modification can significantly improve the targeting capability of the EVs toward neurons both in vivo and in vitro, compared to native EVs [284, 285].”

    From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [285]

    The “RVG peptide modified exosomes for CNS disease treatment” section reports that RVG-targeted exosomes deliver siRNA specifically to the CNS, supporting targeted delivery. It does not establish that RVG29-modified EVs target neurons significantly better than native EVs in both in vivo and in vitro tests; the review’s explicit RVG29 comparison concerns dendrimers, not EVs. Page numbers were not available in our copy. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 9

  1. Gomez-Inhiesto E. Acaiturri-Ayesta M. T. Ustarroz-Aguirre I. Camahuali D. Urtaran-Laresgoiti M. Basabe-Aldecoa M. Nuño-Solinís R. Urizar E. J. Parkinson's Dis. 2020 2020 9106026 PMC7240660 32454967
  2. Cai Q. Wang L. Deng G. Liu J. Chen Q. Chen Z. Am. J. Transl. Res. 2016 8 749 764 27158367 PMC4846924
  3. Manrique-Suarez V. Vispo N. S. Ramos O. S. Curr. Pharm. Biotechnol. 2021 22 1 11 33397231
  4. Rodrigues B. D. Arora S. Kanekiyo T. Singh J. Brain Res. 2020 1734 10 32081534
  5. Potratz M. Zaeck L. M. Weigel C. Klein A. Freuling C. M. Mueller T. Finke S. Acta Neuropathol. Commun. 2020 8 1 15 10.1186/s40478-019-0875-3 33228789 PMC7684951 · DOI
  6. Chung E. P. Cotter J. D. Prakapenka A. V. Cook R. L. DiPerna D. M. Sirianni R. W. J. P. Pharmaceutics 2020 12 93 10.3390/pharmaceutics12020093 PMC7076461 31991664 · DOI
  7. Giarola J. F. Souto D. E. P. Kubota L. T. Anal. Sci. 2021 20P394 33431736
  8. Alvarez-Erviti L. Seow Y. Yin H. Betts C. Lakhal S. Wood M. J. A. Nat. Cell Biol. 2011 29 341 21423189
  9. Chard D. T. Alahmadi A. A. S. Audoin B. Charalambous T. Enzinger C. Hulst H. E. Rocca M. A. Rovira À. Sastre-Garriga J. Schoonheim M. M. Tijms B. Tur C. Gandini Wheeler-Kingshott C. A. M. Wink A. M. Ciccarelli O. Barkhof F. Nat. Rev. Neurol. 2021 1 12 33437067

Cited by

Sorted by citations

Authors
Wang, Q., Cheng, S., Qin, F., Fu, A., & Fu, C.
Affiliations
  • Southwest University (CN)
  • Animal Husbandry Technology
  • The Ninth People's Hospital of Chongqing
Corresponding author
Fu, Chen
Venue
RSC Advances
Published
2021
Volume
11
Issue
15
Pages
8505-8515
ISSN
2046-2069 (ISSN-L)
OpenAlex
W3132110758
Cited by
85
References
108
Citations by year
2026: 24 · 2025: 21 · 2024: 22 · 2023: 11 · 2022: 5 · 2021: 2
FWCI
1.17
Type
journal article
Language
en
Open access
Locations
  • RSC Advances (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Chongqing Science and Technology Commission (cstc2018jcyjAX0612, cstc2018jscx-msybX0304)
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
blood-brain barrier, brain drug delivery, liposomes, micelles, exosomes, dendrimers, polymers, siRNA delivery, microRNA delivery, gene delivery, targeted delivery systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review